TY - JOUR
T1 - Immune Oncology Biomarkers in Lung Cancer
T2 - an Overview
AU - Travert, Camille
AU - Barlesi, Fabrice
AU - Greillier, Laurent
AU - Tomasini, Pascale
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Purpose of Review: Lung cancer is still the first cause of cancer-related deaths worldwide. The development of immune checkpoint inhibitors (ICI) has drastically changed the prognosis of some patients, but the rate of long responders does not exceed 20%. Moreover, ICIs are not adverse events-free and remain expensive. Therefore, predictive biomarkers of long-term benefit to ICI are required. Recent Findings: The two main fields being evaluated currently are PD-L1 expression and tumor mutational burden (TMB). The first one is the only one used in routine practice, and the second is being evaluated in phase 3 clinical trials. In addition, other biomarkers are being assessed as complex signatures, tumor-infiltrated lymphocytes, T cell receptor repertoire, or molecular profiling. Summary: The aim of this review is to summarize the current validated or promising biomarkers in lung cancer which could help to better select patients who will respond to ICI.
AB - Purpose of Review: Lung cancer is still the first cause of cancer-related deaths worldwide. The development of immune checkpoint inhibitors (ICI) has drastically changed the prognosis of some patients, but the rate of long responders does not exceed 20%. Moreover, ICIs are not adverse events-free and remain expensive. Therefore, predictive biomarkers of long-term benefit to ICI are required. Recent Findings: The two main fields being evaluated currently are PD-L1 expression and tumor mutational burden (TMB). The first one is the only one used in routine practice, and the second is being evaluated in phase 3 clinical trials. In addition, other biomarkers are being assessed as complex signatures, tumor-infiltrated lymphocytes, T cell receptor repertoire, or molecular profiling. Summary: The aim of this review is to summarize the current validated or promising biomarkers in lung cancer which could help to better select patients who will respond to ICI.
KW - Immune biomarker
KW - Immune checkpoint inhibitors
KW - Immunotherapy
KW - Lung cancer
KW - PD1/PDL1 axis
KW - Tumor mutational burden
UR - http://www.scopus.com/inward/record.url?scp=85089512372&partnerID=8YFLogxK
U2 - 10.1007/s11912-020-00970-3
DO - 10.1007/s11912-020-00970-3
M3 - Review article
C2 - 32803433
AN - SCOPUS:85089512372
SN - 1523-3790
VL - 22
JO - Current Oncology Reports
JF - Current Oncology Reports
IS - 11
M1 - 107
ER -